Quarterly report pursuant to Section 13 or 15(d)

INVESTMENT (Details Narrative)

v3.22.2.2
INVESTMENT (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Aug. 31, 2022
Aug. 24, 2022
Schedule of Equity Method Investments [Line Items]            
Unrealized gain securities $ 3,727,000   $ 3,727,000      
Principal amount - convertible note 1,000,000   1,000,000      
Accrued interest - convertible note 86,000   86,000      
Unrealized gain on conversion - convertible note $ 271,000 $ 271,000    
Iliad [Member] | Class C Units [Member]            
Schedule of Equity Method Investments [Line Items]            
Ownership percentage not fully diluted 6.90%   6.90%      
I Li A D Biotechnologies L L C [Member]            
Schedule of Equity Method Investments [Line Items]            
Aggregrate investment         $ 7,000,000  
Book value of investment $ 7,000,000   $ 7,000,000      
Private financing - D units           $ 42,836,000
Invested amount - multi-national pharma           30,000,000
Additional invested amount - D units           $ 1,000,000
Iliad [Member]            
Schedule of Equity Method Investments [Line Items]            
Aggregrate investment 7,000,000   7,000,000      
Equity investment net loss $ 285,000 $ 186,000 $ 1,073,000 $ 632,000    
Iliad [Member] | Class C Units [Member]            
Schedule of Equity Method Investments [Line Items]            
Ownership percentage fully diluted     6.40%